CHAMPIONS ONCOLOGY, INC. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum
CHAMPIONS ONCOLOGY, INC. (CSBR) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum of 4.32% for the 3-month period ending 2026-07-31, per its 10-Q filed 2026-09-11.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum · last filed 2026-09-11
- CHAMPIONS ONCOLOGY, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, minimum for the quarter ending 2026-07-31 was 4.32%, a 5.88% increase year-over-year.
- CHAMPIONS ONCOLOGY, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, minimum for the quarter ending 2026-01-31 was 3.75%, a 8.31% decline year-over-year.
- CHAMPIONS ONCOLOGY, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, minimum for the quarter ending 2025-07-31 was 4.08%.
- CHAMPIONS ONCOLOGY, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, minimum for the quarter ending 2025-01-31 was 4.09%.
- CHAMPIONS ONCOLOGY, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, minimum for fiscal 2026 was 3.60%, a 0.00% change from fiscal 2025.
- CHAMPIONS ONCOLOGY, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, minimum for fiscal 2025 was 3.60%, a 10.00% decline from fiscal 2024.
- CHAMPIONS ONCOLOGY, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, minimum for fiscal 2024 was 4.00%, a 37.93% increase from fiscal 2023.
- CHAMPIONS ONCOLOGY, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, minimum for fiscal 2023 was 2.90%, a 262.50% increase from fiscal 2022.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum 9 month as first filed | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum 12 month |
|---|---|---|---|---|---|
| 2026-07-31 | 4.32% 10-Q · filed 2026-09-11 | ||||
| 2026-04-30 | 3.60% 10-K · filed 2026-07-27 | ||||
| 2026-01-31 | 3.75% 10-Q · filed 2026-03-12 | 3.75% 10-Q · filed 2026-03-12 | |||
| 2025-10-31 | 4.08% 10-Q · filed 2025-12-15 | ||||
| 2025-07-31 | 4.08% 10-Q · filed 2026-09-11 | ||||
| 2025-04-30 | 3.60% 10-K · filed 2026-07-27 | ||||
| 2025-01-31 | 4.09% 10-Q · filed 2026-03-12 | 3.58% 10-Q · filed 2026-03-12 | |||
| 2024-10-31 | 3.58% 10-Q · filed 2025-12-15 | 3.58% 10-Q · filed 2025-12-15 | |||
| 2024-04-30 | 4.00% 10-K · filed 2025-07-23 | ||||
| 2024-01-31 | 3.95% 10-Q · filed 2025-03-17 | ||||
| 2023-10-31 | 3.95% 10-Q · filed 2024-12-16 | ||||
| 2023-04-30 | 2.90% 10-K · filed 2024-07-19 | ||||
| 2023-01-31 | 287.00% 10-Q · filed 2024-03-15 | 2.87% 10-Q · filed 2023-03-16 | |||
| 2022-10-31 | 2.87% 10-Q · filed 2022-12-13 | ||||
| 2022-04-30 | 0.80% 10-K · filed 2023-07-24 | ||||
| 2022-01-31 | 1.11% 10-Q · filed 2023-03-16 | 0.82% 10-Q · filed 2023-03-16 | |||
| 2021-10-31 | 0.82% 10-Q · filed 2022-12-13 | ||||
| 2021-04-30 | 0.10% 10-K · filed 2022-07-22 | ||||
| 2021-01-31 | 0.12% 10-Q · filed 2022-03-15 | ||||
| 2020-10-31 | 0.27% 10-Q · filed 2021-12-13 | ||||
| 2020-04-30 | 1.30% 10-K · filed 2021-07-26 | ||||
| 2020-01-31 | 1.57% 10-Q · filed 2021-03-15 | 1.57% 10-Q · filed 2021-03-15 | |||
| 2019-04-30 | 2.60% 10-K · filed 2020-07-28 | ||||
| 2018-04-30 | 1.80% 10-K · filed 2019-07-29 | ||||
| 2018-01-31 | 1.77% 10-Q · filed 2018-03-19 | ||||
| 2017-04-30 | 0.60% 10-K · filed 2018-07-30 | ||||
| 2017-01-31 | 0.59% 10-Q · filed 2018-03-19 | 0.59% 10-Q · filed 2018-03-19 | |||
| 2016-10-31 | 0.75% 10-Q · filed 2017-12-15 | ||||
| 2016-07-31 | 0.75% 10-Q · filed 2017-09-14 | ||||
| 2016-04-30 | 0.60% 10-K · filed 2017-07-28 | ||||
| 2016-01-31 | 1.00% 10-Q · filed 2017-03-17 | 1.00% 10-Q · filed 2017-03-17 | |||
| 2015-10-31 | 1.63% 10-Q · filed 2016-12-14 | 1.57% 10-Q · filed 2016-12-14 | |||
| 2015-07-31 | 1.57% 10-Q · filed 2016-09-14 | ||||
| 2015-04-30 | 0.80% 10-K · filed 2016-07-29 | ||||
| 2015-01-31 | 0.79% 10-Q · filed 2016-03-16 | ||||
| 2014-10-31 | 1.53% 10-Q · filed 2015-12-15 | 0.79% 10-Q · filed 2015-12-15 | |||
| 2014-07-31 | 0.95% 10-Q · filed 2015-09-11 | ||||
| 2014-04-30 | 0.70% 10-K · filed 2015-07-29 | ||||
| 2014-01-31 | 1.40% 10-Q · filed 2015-03-17 | 0.80% 10-Q · filed 2015-03-17 | |||
| 2013-10-31 | 1.13% 10-Q · filed 2014-12-15 | 1.13% 10-Q · filed 2014-12-15 | |||
| 2013-07-31 | 1.38% 10-Q · filed 2014-09-12 | ||||
| 2013-04-30 | 0.70% 10-K · filed 2014-07-28 | ||||
| 2013-01-31 | 0.90% 10-Q · filed 2013-03-13 | 0.80% 10-Q · filed 2013-03-13 | |||
| 2012-10-31 | 0.80% 10-Q · filed 2013-12-13 | ||||
| 2012-07-31 | 0.80% 10-Q · filed 2013-09-13 | ||||
| 2012-04-30 | 0.40% 10-K · filed 2013-07-26 | ||||
| 2012-01-31 | 0.40% 10-Q · filed 2013-03-13 | 0.40% 10-Q · filed 2013-03-13 | |||
| 2011-07-31 | 0.80% 10-Q · filed 2012-09-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| EXOZYMES INC. (EXOZ) | United States | $0.058B | |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |